Loading organizations...
Key people at dievini Hopp Biotech holding.
dievini Hopp Biotech holding was founded in 2005 by Christof Hettich (Co-Founder & MD).
dievini Hopp Biotech Holding is a German life sciences investment firm supporting innovative companies. It focuses on advanced therapeutics and diagnostics, strategically investing in oncology, CNS disorders, cell-based therapies, and personalized medicine. The firm actively cultivates promising biotechnological ventures with direct engagement and capital.
Established in 2005, dievini Hopp Biotech Holding functions as the family office for Dietmar Hopp, co-founder of SAP. The firm originated from Hopp’s vision to propel medical innovation, strategically allocating resources to biological research. Friedrich von Bohlen and Christof Hettich lead, guiding investments across the biotech landscape.
The firm’s partners are life and health sciences companies seeking strategic funding and mentorship. dievini Hopp Biotech Holding aims to accelerate medical breakthroughs by identifying and nurturing high-potential biotechnologies. Its vision centers on advancing personalized medicine and tackling pressing global health challenges.
dievini Hopp Biotech holding was founded in 2005 by Christof Hettich (Co-Founder & MD).
Key people at dievini Hopp Biotech holding.
dievini Hopp Biotech holding has 5 tracked investments across 2 companies. The latest tracked deal is $58.0M Series E in immatics biotechnologies in October 2017.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2017 | immatics biotechnologies | $58.0M Series E | — | Wellington Partners, Amgen Ventures, AT Impf |
| Jul 1, 2014 | immatics biotechnologies | $30.0M Series D | — | Wellington Partners, AT Impf |
| Oct 1, 2013 | immatics biotechnologies | $16.0M Series D | — | Wellington Partners, AT Impf, MIG Capital |
| Sep 1, 2010 | immatics biotechnologies | $71.0M Series C | — | Wellington Partners, AT Impf, Matthias Kromayer |
| Oct 1, 2009 | Integrated Diagnostics | $30.0M Series A | Interwest Partners | InterWest |
